文献速递神经肿瘤

单次立体定向放射外科治疗非典型脑膜瘤(WHO II级):25年经验

The role of single-fraction stereotactic radiosurgery for atypical meningiomas (WHO grade II): treatment results based on a 25-year experience.
PubMed 文献 · J Neurooncol · 2021-10-27

该回顾性研究分析1995至2019年68例接受立体定向放射外科(SRS)的非典型脑膜瘤患者,中位随访52个月。3年、5年、10年无进展生存率分别为52%、35%、25%,疾病特异性生存率分别为85%、78%、61%。既往外照射放疗与更差的无进展生存、疾病特异性生存及更高不良放疗事件风险相关。

要点

  • SRS后非典型脑膜瘤长期无进展生存仍不理想,10年PFS仅25%。
  • 既往外照射放疗与PFS、DSS降低及不良放疗事件风险增加相关。
  • 早期挽救性SRS较 upfront 辅助SRS与更差PFS相关,SRS时机需进一步研究。

核心结论

  • 尽管接受SRS,残留或复发非典型脑膜瘤患者的无进展生存仍较差。
  • 既往外照射放疗与更差肿瘤控制、更高肿瘤相关死亡及不良放疗事件风险增加相关。
  • 需进一步研究SRS时机以明确 upfront 辅助SRS是否较挽救性SRS改善肿瘤控制。

研究设计与样本

  • 回顾性分析1995年至2019年68例接受SRS的非典型脑膜瘤患者。
  • 19例(28%)既往接受外照射放疗,中位剂量54 Gy。
  • 中位随访52个月;SRS作为 upfront 辅助(≤6个月)18例(26%)、早期挽救(7-18个月)17例(25%)、晚期挽救(>18个月)33例(49%)。

主要发现

  • 3年、5年、10年无进展生存率分别为52%、35%、25%。
  • 3年、5年、10年疾病特异性生存率分别为85%、78%、61%。
  • 12例(18%)出现不良放疗事件,最常见为癫痫发作增加或新发(n=7)。
  • 既往外照射放疗与PFS降低(HR 5.92,P < 0.01)、DSS降低(HR 5.84,P < 0.01)及不良放疗事件风险增加(HR 3.31,P = 0.04)相关。
  • 早期挽救性SRS较 upfront 辅助SRS(HR 3.17,P = 0.01)或晚期挽救性SRS(HR 4.39,P < 0.01)与PFS降低相关。

临床怎么用

  • 对残留或复发非典型脑膜瘤,SRS后需密切随访,长期无进展生存有限。
  • 既往接受外照射放疗者SRS后肿瘤控制更差且不良放疗事件风险更高,应加强监测。
  • SRS时机选择需个体化,早期挽救性SRS可能预后更差, upfront 辅助SRS的价值待进一步研究。

局限性

  • 回顾性研究设计,样本量68例,存在选择偏倚可能。
  • SRS时机分组非随机,混杂因素可能影响结果解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To clarify the role of stereotactic radiosurgery (SRS) for atypical meningiomas (AM). METHODS: A retrospective analysis of 68 patients with AM having SRS from 1995 until 2019. RESULTS: Nineteen patients (28%) had undergone prior external beam radiation therapy (EBRT) (median dose, 54 Gy). The median follow-up period was 52 months. Eighteen (26%), 17 (25%), and 33 (49%) patients received SRS as an upfront adjuvant (≤ 6 months), early salvage (7-18 months), or late salvage treatment (> 18 months), respectively. The 3-, 5-, and 10-year progression-free survivals (PFSs) were 52%, 35%, and 25%, respectively. The 3-, 5-, and 10-year disease-specific survivals were 85%, 78%, and 61%, respectively. Adverse radiation events (AREs) were observed in 12 patients (18%), with increased or new seizures being the most frequent complication (n = 7). Prior EBRT was associated with reduced PFS (HR 5.92, P < 0.01), reduced DSS (HR 5.84, P < 0.01), and an increased risk of ARE (HR 3.31, P = 0.04). Timing of SRS was correlated with reduced PFS for patients having early salvage treatment compared to upfront adjuvant (HR 3.17, P = 0.01) or late salvage treatment (HR 4.39, P < 0.01). CONCLUSION: PFS for patients with residual/recurrent AM remains poor despite SRS. Prior EBRT was associated with worse tumor control, higher tumor-related mortality, and an increased risk of ARE. Further study on the timing of SRS is needed to determine if upfront adjunctive SRS improves tumor control compared to salvage SRS.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Hasegawa H, Vakharia K, Link MJ, et al. The role of single-fraction stereotactic radiosurgery for atypical meningiomas (WHO grade II): treatment results based on a 25-year experience. J Neurooncol. 2021. PMID: 34705189. doi:10.1007/s11060-021-03882-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。